Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. Article uri icon

Overview

publication date

  • November 27, 2018

Research

keywords

  • Antineoplastic Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Receptors, Antigen, B-Cell
  • Sulfonamides

Identity

PubMed Central ID

  • PMC6587980

Scopus Document Identifier

  • 85057283456

Digital Object Identifier (DOI)

  • 10.1111/bjh.15666

PubMed ID

  • 30478940

Additional Document Info

volume

  • 185

issue

  • 5